Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and cysteine

irinotecan has been researched along with cysteine in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (72.73)29.6817
2010's3 (27.27)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cao, S; Durrani, FA; Rustum, YM1
Azrak, RG; Cao, S; Durrani, FA; Frank, C; Li, ZR; Rustum, YM; Yin, MB1
Azrak, RG; Cao, S; Durrani, FA; Li, X; McLeod, HL; Pendyala, L; Rustum, YM; Shannon, WD; Smith, PF; Yu, J1
Cao, S; Durrani, FA; Fakih, M; Rustum, YM1
Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Frank, C; Hapke, G; Li, ZR; Rustum, YM; Tóth, K; Yin, MB1
Ewis, HE; Liu, P; Lu, CD; Tai, PC; Weber, IT1
Azrak, RG; Cao, S; Combs, GF; Durrani, FA; Fakih, M; Pendyala, L; Prey, J; Rustum, YM; Smith, PF1
Bhattacharya, A; Cao, S; Chintala, S; Durrani, FA; Rustum, YM; Slocum, HK; Tóth, K1
Cao, S; Chintala, S; Durrani, FA; Jensen, RL; Rustum, YM; Tóth, K; Vaughan, MM1
Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Rustum, YM; Toth, K1

Reviews

2 review(s) available for irinotecan and cysteine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine; Drug Synergism; Humans; Irinotecan; Mice; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Selenomethionine

2005

Other Studies

9 other study(ies) available for irinotecan and cysteine

ArticleYear
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Apr-01, Volume: 10, Issue:7

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors

2004
Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.
    Molecular pharmacology, 2004, Volume: 66, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carbon-Sulfur Lyases; Caspase 3; Caspases; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Cysteine; DNA Fragmentation; Drug Interactions; Enzyme Activation; Gene Expression; Humans; Irinotecan; Minichromosome Maintenance Complex Component 2; Nuclear Proteins; Organoselenium Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Saccharomyces cerevisiae Proteins; Selenocysteine

2004
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cysteine; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Pharmacogenetics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Selenocysteine; Transplantation, Heterologous; Tumor Cells, Cultured

2005
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiog
    Oncogene, 2006, Apr-20, Volume: 25, Issue:17

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cysteine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Organoselenium Compounds; Selenocysteine; Transplantation, Heterologous

2006
Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
    Journal of molecular biology, 2007, Mar-16, Volume: 367, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Bacillaceae; Binding Sites; Camptothecin; Carboxylesterase; Crystallization; Crystallography; Cysteine; Iodine; Irinotecan; Models, Molecular; Prodrugs; Protein Conformation

2007
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Biochemical pharmacology, 2007, May-01, Volume: 73, Issue:9

    Topics: Administration, Oral; Animals; Bone Marrow; Camptothecin; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Kidney; Kinetics; Liver; Mice; Mice, Nude; Neoplasms; Organoselenium Compounds; Plasma; Selenium; Selenocysteine

2007
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Neoplasia (New York, N.Y.), 2008, Volume: 10, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cysteine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Selenocysteine; Tirapazamine; Triazines; Xenograft Model Antitumor Assays

2008
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:5

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Cell Hypoxia; Cysteine; Drug Delivery Systems; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Reactive Oxygen Species; RNA, Small Interfering; Selenocysteine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
    Cancer letters, 2011, Dec-08, Volume: 311, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Chromatography, High Pressure Liquid; Cysteine; Drug Synergism; Female; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Organoselenium Compounds; Selenocysteine; Xenograft Model Antitumor Assays

2011